Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feeling cold08.01.09.008--Not Available
Feeling hot08.01.09.009--Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Fibrosis08.03.01.001--Not Available
Fistula15.03.02.0010.001066%Not Available
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Folliculitis23.09.04.007; 11.01.12.0180.000533%
Food allergy10.01.01.012--Not Available
Foot fracture12.04.01.012; 15.08.03.012--Not Available
Formication19.10.02.010; 17.02.06.0180.000799%Not Available
Fracture15.08.02.001; 12.04.02.0010.003463%
Frequent bowel movements07.02.04.002--Not Available
Fungal infection11.03.05.001--Not Available
Fungal skin infection11.03.05.002; 23.09.02.0010.000533%Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gamma-glutamyltransferase increased13.03.01.011--
Gastric cancer16.13.03.001; 07.21.02.0010.000834%Not Available
Gastric dilatation07.02.02.0020.000533%Not Available
Gastric haemorrhage24.07.02.007; 07.12.01.001--
Gastric perforation12.02.03.007; 07.04.03.0010.000799%
Gastric ulcer07.04.03.002--
Gastritis07.08.02.0010.001865%
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.0010.001066%Not Available
Gastroenteritis viral11.05.04.005; 07.19.03.005--Not Available
Gastrointestinal candidiasis07.19.02.003; 11.03.03.011--Not Available
Gastrointestinal disorder07.11.01.0010.015452%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 35 Pages